Recently, Eagle K et al. integrated pan-cancer genetic dependency data with that of a comprehensive enhancer landscape and identified SEPHS2, a selenoprotein biosynthesis gene, as a highly AML-selective dependency encoded by a Myb-regulated oncogenic enhancer. The gene discussed is SELENOS; the disease is cancer.